Human TNF receptor
DC CAFC
First Claim
Patent Images
1. A method comprising the steps of:
- (a) culturing a host cell comprising a polynucleotide, wherein the polynucleotide encodes a protein consisting of;
(i) the extracellular region of an insoluble human TNF receptor, wherein the insoluble human TNF receptor has an apparent molecular weight of about 75 kilodaltons as determined on a non-reducing SDS-polyacrylamide gel and comprises the amino acid sequence LPAQVAFXPYAPEPGSTC (SEQ ID NO;
10), and(ii) all of the domains of the constant region of a human IgG immunoglobulin heavy chain other than the first domain of said constant region, and(b) purifying an expression product of the polynucleotide from the cell mass or the culture medium.
0 Assignments
Litigations
2 Petitions
Accused Products
Abstract
The present invention is concerned with non-soluble proteins and soluble or insoluble fragments thereof, which bind TNF, in homogeneous form, as well as their physiologically compatible salts, especially those proteins having a molecular weight of about 55 or 75 kD (non-reducing SDS-PAGE conditions), a process for the isolation of such proteins, antibodies against such proteins, DNA sequences which code for non-soluble proteins and soluble or non-soluble fragments thereof, which bind TNF, as well as those which code for proteins comprising partly of a soluble fragment, which binds TNF, and partly of all domains except the first of the constant region of the heavy chain of human immunoglobulins and the recombinant proteins coded thereby as well as a process for their manufacture using transformed pro- and eukaryotic host cells.
75 Citations
10 Claims
-
1. A method comprising the steps of:
-
(a) culturing a host cell comprising a polynucleotide, wherein the polynucleotide encodes a protein consisting of; (i) the extracellular region of an insoluble human TNF receptor, wherein the insoluble human TNF receptor has an apparent molecular weight of about 75 kilodaltons as determined on a non-reducing SDS-polyacrylamide gel and comprises the amino acid sequence LPAQVAFXPYAPEPGSTC (SEQ ID NO;
10), and(ii) all of the domains of the constant region of a human IgG immunoglobulin heavy chain other than the first domain of said constant region, and (b) purifying an expression product of the polynucleotide from the cell mass or the culture medium. - View Dependent Claims (2, 3)
-
-
4. A polynucleotide encoding a protein consisting of:
-
(a) the extracellular region of an insoluble human TNF receptor, wherein the insoluble human TNF receptor (i) has an apparent molecular weight of about 75 kilodaltons as determined on a non-reducing SDS-polyacrylamide gel and (ii) comprises the amino acid sequence LPAQVAFXPYAPEPGSTC (SEQ ID NO;
10), and(b) all of the domains of the constant region of a human IgG1 immunoglobulin heavy chain other than the first domain of said constant region. - View Dependent Claims (5, 6)
-
-
7. A method comprising the steps of:
-
(a) culturing a host cell comprising a polynucleotide, wherein the polynucleotide encodes a protein consisting of; (i) the extracellular region of an insoluble human TNF receptor, wherein the insoluble human TNF receptor comprises the amino acid sequence of SEQ ID NO;
27 and(ii) all of the domains of the constant region of a human IgG immunoglobulin heavy chain other than the first domain of said constant region, and (b) purifying an expression product of the polynucleotide from the cell mass or the culture medium. - View Dependent Claims (8, 9, 10)
-
Specification
-
- Resources
Litigation Campaign Assessment
Thank you for your request. You will receive a custom alert email when the Litigation Campaign Assessment is available.
×
Litigation Data
-
Current AssigneeHoffmann-La Roche Incorporated (Roche Holding AG)
-
Original AssigneeHoffmann-La Roche Incorporated (Roche Holding AG)
-
InventorsBrockhaus, Manfred, Gentz, Reiner, Zlatko, Dembic, Lesslauer, Werner, Lotscher, Hansruedi, Schlaeger, Ernst-Jurgen
-
Primary Examiner(s)SCHWADRON, RONALD B
-
Application NumberUS08/444,791Time in Patent Office6,185 DaysField of Search530/350, 530/385, 530/388.22, 530/387.1, 530/866, 530/867, 530/391.1, 636/23.53, 636/23.1, 435/69.7, 435/70.21, 435/320.1, 536/23.4US Class Current435/69.9CPC Class CodesA61K 38/00 Medicinal preparations cont...A61P 29/00 Non-central analgesic, anti...A61P 31/04 Antibacterial agentsA61P 37/06 Immunosuppressants, e.g. dr...C07K 14/7151 for tumor necrosis factor [...C07K 16/2866 against receptors for cytok...C12N 2799/026 where the vector is derived...Y10S 930/144 Tumor necrosis factor
